Because tumor initiating cells or cancer stem cells have been thought to have undergone epigenetic reprogramming [36, 37], we sought to determine if D9 as a histone methylation inhibitor would be effective in targeting AML leukemia stem cells (LSCs). Here, CENPX is linked to acute myeloid leukemia.